Literature DB >> 18355631

Magnetic resonance imaging and spectroscopy in a mouse model of schizophrenia.

German Torres1, Brian H Hallas, Kenneth W Gross, Joseph A Spernyak, Judith M Horowitz.   

Abstract

Metabolic brain abnormalities, as demonstrated by (1)H-magnetic resonance spectroscopy, are common occurrences in adult schizophrenia. As mice share important biochemical and genomic similarities with humans, we tested whether brain metabolic abnormalities also occur in a transgenic mouse model of schizophrenia. In vivo(1)H-magnetic resonance spectroscopy at 4.7T of the chakragati mouse brain revealed abnormalities in relative levels of choline and N-acetylaspartate compounds. These results are consistent with a prior proposal that deficits in metabolite ratios may be common features of psychotic disorders. Thus, chakragati mice recapitulate certain aspects of the human disease phenotype and further support the utility of this animal model for understanding causal factors underlying uniquely human brain diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18355631      PMCID: PMC2359223          DOI: 10.1016/j.brainresbull.2007.09.006

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  28 in total

Review 1.  Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models.

Authors:  Jingshan Chen; Barbara K Lipska; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2006-05-02       Impact factor: 13.382

Review 2.  Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia.

Authors:  W S Fenton; J Hibbeln; M Knable
Journal:  Biol Psychiatry       Date:  2000-01-01       Impact factor: 13.382

3.  Ventricular size mapping in a transgenic model of schizophrenia.

Authors:  German Torres; Beth A Meeder; Brian H Hallas; Joseph A Spernyak; Richard Mazurchuk; Craig Jones; Kenneth W Gross; Judith M Horowitz
Journal:  Brain Res Dev Brain Res       Date:  2005-01-01

4.  N-Acetylaspartate concentration in the anterior cingulate of maltreated children and adolescents with PTSD.

Authors:  M D De Bellis; M S Keshavan; S Spencer; J Hall
Journal:  Am J Psychiatry       Date:  2000-07       Impact factor: 18.112

5.  Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls.

Authors:  D A Yurgelun-Todd; P F Renshaw; S A Gruber; M Ed; C Waternaux; B M Cohen
Journal:  Schizophr Res       Date:  1996-03       Impact factor: 4.939

Review 6.  Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour.

Authors:  Colm M P O'Tuathaigh; Daniela Babovic; Gillian O'Meara; Jeremiah J Clifford; David T Croke; John L Waddington
Journal:  Neurosci Biobehav Rev       Date:  2006-06-19       Impact factor: 8.989

7.  Preliminary evidence for reduced social interactions in Chakragati mutants modeling certain symptoms of schizophrenia.

Authors:  German Torres; Beth A Meeder; Brian H Hallas; Kenneth W Gross; Judith M Horowitz
Journal:  Brain Res       Date:  2005-06-07       Impact factor: 3.252

8.  Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo.

Authors:  D M Lindquist; R M Hawk; C N Karson; R A Komoroski
Journal:  Magn Reson Med       Date:  2000-03       Impact factor: 4.668

Review 9.  The molecular genetics of the 22q11-associated schizophrenia.

Authors:  Maria Karayiorgou; Joseph A Gogos
Journal:  Brain Res Mol Brain Res       Date:  2004-12-20

10.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.

Authors:  G Tsai; L A Passani; B S Slusher; R Carter; L Baer; J E Kleinman; J T Coyle
Journal:  Arch Gen Psychiatry       Date:  1995-10
View more
  1 in total

Review 1.  Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders.

Authors:  Moonnoh R Lee; Aleksandar Denic; David J Hinton; Prasanna K Mishra; Doo-Sup Choi; Istvan Pirko; Moses Rodriguez; Slobodan I Macura
Journal:  Bioanalysis       Date:  2012-07       Impact factor: 2.681

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.